Effects of Somatostatin Analogue SMS 201.995 on Rectal Cancer
Author Information
Author(s): S.Y. Iftikhar, S.A. Watson, D.L. Morris
Primary Institution: University Hospital, Nottingham
Hypothesis
Can the somatostatin analogue SMS 201.995 inhibit the growth of colorectal cancers?
Conclusion
The study provides initial clinical evidence that SMS 201.995 can inhibit the growth of some colorectal cancers.
Supporting Evidence
- Four out of 12 patients showed a significant decrease in Ki67 immunoreactivity during treatment.
- Two out of four patients with elevated CEA levels had a modest reduction during therapy.
- Ki67 antigen expression correlates with tumor growth in colorectal cancers.
Takeaway
Doctors tested a medicine called SMS 201.995 on 12 patients with rectal cancer to see if it could help slow down the cancer's growth.
Methodology
Patients with primary rectal adenocarcinoma were treated with SMS 201.995 for 14 days, and tumor responses were assessed using serum markers and Ki67 immunoreactivity.
Potential Biases
Treatment allocation was not random, as control patients were those who declined treatment.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Patients had histologically confirmed primary rectal adenocarcinoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website